Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rare Pediatric Disease Priority Review Voucher
Pharma
Ultragenyx cashes in a pair of FDA review vouchers for $413M
Hot off a pair of key FDA approvals this summer, Ultragenyx has wasted little time cashing in on a pair of priority review vouchers it earned.
Fraiser Kansteiner
Oct 14, 2026 4:19pm
Rocket nets $180M in priority review voucher sale
Apr 28, 2026 11:16am
Fortress sells FDA voucher for $205M after Zycubo approval
Feb 23, 2026 10:15am
FDA’s rare pediatric voucher program revived by funding bill
Feb 4, 2026 3:12pm
Sentynl, Cyprium score FDA nod for 1st med for Menkes disease
Jan 13, 2026 10:45am
House vote moves FDA's rare PRV program a step closer to revival
Dec 2, 2025 11:22am
